<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2017031533055N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-05-30</date_registration>
      <primary_sponsor>Ahwaz JundiShapur University of Medical Sciences</primary_sponsor>
      <public_title>Comparison effect of sodium nitroprusside effect on reducing of incidence and duration of atrial fibrillation after coronary artery bypass graft surgery</public_title>
      <acronym>does not have</acronym>
      <scientific_title>Comparison effect of sodium nitroprusside effect on reducing of incidence and duration of atrial fibrillation after coronary artery bypass graft surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-04-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>52</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/25599</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Other design features: This study is a randomized, double-blind, prospective, randomized controlled study for comparison of the effect of sodium nitroprusside in reducing the incidence and duration of atrial fibrillation after coronary artery bypass graft surgery in patients who are at the heart of Ahwaz Golestan hospital Bbymarstan you will Shvndanjam. Before the operation the patients provided written informed consent form and questionnaire included age, sex, weight, BMI original complaint, a family history of heart disease pre Machvr (first-degree relative under 65 and men under 55 years old), presence of hypertension (pressure ≥140 systolic and / or diastolic BP ≥90), dyslipidemia (increased triglycerides, cholesterol, LDL, decreased HDL), diabetes mellitus (fasting blood glucose ≥ mg / dl 126 (smoking and use of information by researcher interviewing patients the case is completed.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Atrial Fibrillation.</hc_freetext>
      <i_freetext>Intervention 1: During the surgical treatment group and re-warming period starting dose of sodium nitroprusside Mg / Kg / Min 5-1% for 60 minutes will receiveSo that the mean arterial pressure without drugs or drugs Anytrvp increase of intravascular volume is maintained at 65 mm Hg. Intervention 2: Patients in the control group from start to finish re-serum dextrose water 5 percent to 200 cc, but 60 minutes into receive.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyed Mostafa Ariafar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>The Training Center, Golestan Hospital</address>
        <city>Ahwaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 61 3374 3352</telephone>
        <email>Armx51@yahoo.com</email>
        <affiliation>Ahwaz Jundishapur University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Ali Sheikhi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahvaz, Golestan Hospital, Department of Heart</address>
        <city>Ahwaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 61 3374 3036</telephone>
        <email>Sheikhi.MA@YAHOO.COM</email>
        <affiliation>Ahwaz Jundishapur University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: All patients who underwent coronary artery bypass surgery are; patients older than 18 years; would like to participate in the study. Exclusion criteria: history of atrial fibrillation; history of surgery for coronary artery bypass; a history of severe disease; valvular; surgery to repair or replace the valve; the candidate of the current surgical repair or replace the valve; atrium size greater than normal echo cardiogram before surgery; history of anemia or severe electrolyte abnormalities before surgery; history of thyroid disease; syndrome sick sinus; bradycardia and significant changes in atrial conduction; patients with a permanent pacemaker fitted.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I48</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Atial Fibrillation and flutter</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>During the surgical treatment group and re-warming period starting dose of sodium nitroprusside Mg / Kg / Min 5-1% for 60 minutes will receiveSo that the mean arterial pressure without drugs or drugs Anytrvp increase of intravascular volume is maintained at 65 mm Hg.</i_keyword>
      <i_keyword>Patients in the control group from start to finish re-serum dextrose water 5 percent to 200 cc, but 60 minutes into receive.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The incidence of atrial fibrillation after coronary artery bypass surgery. Timepoint: Within 5 days after coronary artery bypass surgery every day. Method of measurement: Within 5 days after coronary artery bypass surgery patients daily 12-lead ECG is taken. Start and end of each episode of atrial Fyrylasyvn recorded by the doctor.</prim_outcome>
      <prim_outcome>Time Dora atrial fibrillation after coronary artery bypass surgery. Timepoint: Within 5 days after coronary artery bypass surgery every day. Method of measurement: Within 5 days after coronary artery bypass surgery patients daily 12-lead ECG is taken. Start and end of each episode of atrial Fyrylasyvn recorded by the doctor.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Onset atrial fibrillation after coronary artery bypass surgery. Timepoint: Within 5 days after surgery daily. Method of measurement: 12-lead ECG is taken daily for 5 days.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahwaz JundiShapur University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-02-07</approval_date>
        <contact_name>Ahwaz JundiShapur University of Medical Sciences</contact_name>
        <contact_address>Ahwaz Golestan University of Medical Sciences Jundishapur Ahwaz  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
